Yes, several treatments widely described as breakthroughs are already in human trials, and a few have crossed the finish line into full FDA approval. The answer depends on which breakthrough you’re tracking, since the term gets applied to everything from cancer vaccines to gene editing to brain implants. Here’s where the most talked-about experimental treatments stand right now.
Personalized mRNA Cancer Vaccines
Moderna and Merck’s mRNA cancer vaccine, known as V940 or mRNA-4157, is in a Phase 3 human trial for high-risk melanoma. The study, called INTerpath-001, tests whether a personalized mRNA vaccine given alongside an existing immunotherapy drug can prevent melanoma from returning after surgery. The trial is listed as open, though it is not currently recruiting new participants.
This vaccine works differently from traditional vaccines. Instead of preventing infection, it trains the immune system to recognize and attack proteins unique to each patient’s tumor. Earlier Phase 2 results showed enough promise to earn the combination a Breakthrough Therapy designation from the FDA, which fast-tracked it into this larger trial. If Phase 3 results hold up, approval could follow within a few years, since Phase 3 trials typically run one to four years.
Gene Editing for Heart Disease
A gene editing treatment called VERVE-101 became the first of its kind to be tested inside the human body for cholesterol reduction. The Phase 1b trial, called Heart-1, enrolled 10 participants with an inherited form of dangerously high cholesterol. Results presented at the American Heart Association’s 2023 meeting showed the single intravenous infusion did lower cholesterol-producing gene activity, but also raised some safety signals: temporary liver enzyme spikes at higher doses and three serious cardiovascular events in two participants.
This is still very early. Phase 1b trials are primarily designed to test safety and find the right dose, not prove the treatment works at scale. But the significance is hard to overstate. If gene editing can safely and permanently lower cholesterol with a single infusion, it could eventually replace the daily pills or biweekly injections millions of people currently rely on.
CAR-T Therapy for Solid Tumors
CAR-T cell therapy, which reprograms a patient’s own immune cells to hunt cancer, has been approved for years for blood cancers like leukemia and lymphoma. The breakthrough question now is whether it can work against solid tumors, which are far harder for immune cells to penetrate. Multiple human trials are underway.
The most promising results so far include a trial where modified immune cells targeting two proteins on brain tumors caused tumor shrinkage in all six patients with recurrent glioblastoma. Other active trials are testing CAR-T cells against gastric cancer, pancreatic cancer, mesothelioma, non-small cell lung cancer, ovarian cancer, sarcoma, and neuroblastoma. A trial for pancreatic cancer has treated 24 patients with advanced, heavily pretreated disease. Another ongoing Phase 1-2 trial is combining CAR-T cells with an RNA vaccine to boost the engineered cells’ activity against ovarian, breast, and gastric tumors, among others.
Most of these are still in Phase 1 or Phase 2, meaning researchers are establishing safety and looking for early signs of effectiveness. Solid tumor CAR-T therapy is likely years from widespread approval, but it is very much in human testing.
Brain-Computer Interfaces
Neuralink’s PRIME study, which implants a brain-computer interface to let paralyzed individuals control digital devices with their thoughts, began its first human implant in January 2024. The trial plans to enroll 15 participants and is actively recruiting. This is an early-stage trial focused on safety and basic functionality, not a treatment headed for mass-market approval anytime soon, but it has moved firmly out of animal testing and into people.
Alzheimer’s Treatments
One major breakthrough has already moved past human trials entirely. Donanemab, an antibody that clears amyloid plaques from the brain, received full FDA approval in July 2024 under the brand name Kisunla. It’s approved for adults with mild cognitive impairment or mild dementia from Alzheimer’s disease and is given as an intravenous infusion every four weeks. The FDA granted it Breakthrough Therapy, Fast Track, and Priority Review designations on the way to approval.
This doesn’t mean it’s a cure. The drug slows cognitive decline rather than stopping or reversing it, and it carries risks including brain swelling and bleeding that require monitoring with regular brain scans. But for people in early stages of Alzheimer’s, it represents a treatment option that didn’t exist a few years ago.
mRNA Flu Vaccines
Next-generation flu vaccines built on the same mRNA technology behind COVID vaccines are in Phase 2 and Phase 3 human trials. A Phase 2a trial run by Pfizer tested an mRNA flu vaccine against a traditional flu shot in healthy adults aged 18 to 55, showing superior protection against symptomatic illness. A separate Phase 3 trial also found better effectiveness with an mRNA vaccine compared to a standard shot, with stronger immune responses to key flu strains, though side effects were more common. Moderna has also pursued FDA review of its own mRNA flu vaccine, though the regulatory path has hit some procedural bumps.
What “Breakthrough” Actually Means
It’s worth knowing that “breakthrough” has a specific regulatory meaning at the FDA, separate from how the media uses the word. To earn a Breakthrough Therapy designation, a drug must treat a serious or life-threatening condition and show preliminary clinical evidence of substantial improvement over existing treatments. The designation doesn’t mean the drug is proven to work. It means the FDA will speed up its review process and work more closely with the developer to get it evaluated faster.
Hundreds of drugs carry this designation at any given time. Some succeed, others fail in later trials. The designation is a signal of promise, not a guarantee.
How to Check a Trial’s Status Yourself
If you’re tracking a specific treatment, ClinicalTrials.gov is the most reliable place to check. You can search by drug name, condition, or a trial’s unique NCT number. The results page shows two key pieces of information: the trial’s phase (Phase 1 through Phase 4) and its recruitment status (recruiting, not yet recruiting, completed, or terminated).
To put those phases in practical terms: Phase 1 trials typically last several months and test safety in a small group. Phase 2 trials run several months to two years and look for early evidence the treatment works. Phase 3 trials take one to four years and test the treatment in large groups to confirm effectiveness and monitor side effects. Only after a successful Phase 3 trial can a company apply for FDA approval. From first human trial to pharmacy shelf, the full process often takes six to ten years, though Breakthrough Therapy designation and other fast-track pathways can compress that timeline significantly.